Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus NYSTAFORM.
MICONAZOLE 7 vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Primarily fecal (~50%) and renal (~<1% unchanged)
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category A/B
Category C
Antifungal
Antifungal